Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00625768
Other study ID # AS1409-101
Secondary ID
Status Completed
Phase Phase 1
First received February 20, 2008
Last updated August 24, 2009
Start date January 2008
Est. completion date April 2009

Study information

Verified date August 2009
Source Antisoma Research
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose of AS1409 in single and repeated doses.


Description:

- To determine the tolerability, safety, end-organ toxicity and maximum tolerated dose (MTD) of AS1409 in single and repeated doses.

- To determine biological responses to AS1409, including interferon-γ and IP-10 circulating concentrations.

- To determine preliminary pharmacokinetics of AS1409.

- To determine the immunogenicity of AS1409

- To explore the anti-tumour activity of AS1409.


Recruitment information / eligibility

Status Completed
Enrollment 13
Est. completion date April 2009
Est. primary completion date April 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Be 18 years or older at the time of giving informed consent.

- Histologically confirmed diagnosis of renal cell carcinoma or malignant melanoma.

- If renal cell carcinoma, of clear cell or chromophilic/papillary type, with metastases at any site (but excluding patients with single bony lesion only).

- If malignant melanoma, unresectable Stage III disease or Stage IV disease, with metastases at any site (but excluding patients with single bony lesion only)

- Patients with clinically stable CNS metastases may enter who have been treated with surgery or radiation and who do not require steroid therapy.

- ECOG performance status 0-2.

- Patients who have received prior systemic treatment for their malignancy with chemotherapeutic or biological therapies may enter, provided treatment was completed within 4 weeks of study entry.

- Patients who have received prior experimental therapy may enter, provided treatment was completed within 12 weeks of study entry.

- Have adequate bone marrow function as evidenced by neutrophils >1.5 x109/L and platelets >100 x109/L.

- Have adequate liver and kidney function, as shown by serum bilirubin =1.5x upper limit of normal for the laboratory; ALT and AST both =2x upper limit of normal; and creatinine =1.5x upper limit of normal.

- Have either evaluable or measurable disease (patients entering an ascending dosage cohort) or measurable disease (patients entering the study after MTD is defined).

- Patients who have failed and or are ineligible for standard first line therapy (in accordance with individual institutional practice)

Exclusion Criteria:

Patients with any of the following will be excluded from the study:

- Patients at poor medical risk because of non-malignant systemic disease or active infection.

- History of clinically significant autoimmune or predominantly Th1-driven clinical disorders (such as rheumatoid arthritis, psoriasis, chronic inflammatory bowel disease, for example), with the exception of autoimmune endocrinopathies now treated with replacement therapy.

- Diabetic retinopathy.

- Substantive surgery within 4 weeks prior to study entry, or expectation of surgery during the study period.

- Malignancy other than renal cell carcinoma or malignant melanoma within 5 years of study entry, except for non-melanoma skin cancer and cervical intraepithelial neoplasia treated definitively or other cancer from which the patient has been disease-free for 5 years.

- Concurrent treatment with systemic steroids or with other immunosuppressive therapies.

- If female, pregnant or breastfeeding;

- Women of child bearing potential or sexually active males, unless (1) the patient (if female, or the patient's partner, if male) is surgically sterile or (2) using adequate contraception (defined as either IUD, oral or depot contraceptive, or barrier plus spermicide) while receiving study treatment and for at least 6 months after termination of treatment. Women must be post-menopausal for at least 2 years to be considered of non-childbearing potential

- Any concurrent medical or psychological condition that would limit the ability of the patient to provide informed consent or to comply with the obligations of the study.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
AS1409
Study drug

Locations

Country Name City State
New Zealand Auckland Medical School Auckland
New Zealand Waikato DHB Hamilton
United Kingdom Charing Cross Hospital London
United Kingdom Guys Hospital London

Sponsors (1)

Lead Sponsor Collaborator
Antisoma Research

Countries where clinical trial is conducted

New Zealand,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumor assessment 6 weeks, response confirmed at 4 weeks No
Primary Biomarkers (interferon-? and IP-10 Interferon) Various timepoints cycles 1-6, pre- and post-dose; then 1,4 and 12 weeks post last dose No
Primary Adverse event monitoring Various timepoints cycles 1-6, pre- and post-dose; then 1,4 and 12 weeks post last dose Yes
See also
  Status Clinical Trial Phase
Completed NCT00930033 - Clinical Trial to Assess the Importance of Nephrectomy Phase 3
Recruiting NCT05863351 - Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study Phase 3
Not yet recruiting NCT06284564 - A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC) Phase 2
Completed NCT00414765 - Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma Phase 4
Active, not recruiting NCT03149822 - Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma Phase 1/Phase 2
Recruiting NCT03647878 - Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Completed NCT01517243 - Phase II Study of Alternating Sunitinib and Temsirolimus Phase 2
Withdrawn NCT03927248 - PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer Phase 1/Phase 2
Terminated NCT02122003 - Second Line Sorafenib After Pazopanib in Patients With RCC Phase 2
Completed NCT01182142 - Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients Phase 2
Completed NCT00630409 - Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Completed NCT04076787 - Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Active, not recruiting NCT04467021 - Cancer and Blood Pressure Management, CARISMA Study N/A
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Completed NCT02282579 - Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
Terminated NCT02071641 - Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma Phase 2
Completed NCT01731158 - Sequential Therapy in Metastatic Renal Cell Carinoma Phase 2
Terminated NCT01342627 - Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma Phase 2
Active, not recruiting NCT01274273 - Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer Phase 2